PicoBlog

Finally, some reason! I was one of your CRM reps at Guidant when we met. I was with Guidant then Boston Scientific when Watchman was being developed. I was not impressed. Certainly we could do better. Exchanging one systemic therapy for a focal therapy without clear systemic benefit is immoral. But Watchman will make a lot of money for BSC and has already made some careers.

Expand full comment

ncG1vNJzZmiin527rq3NnamopJFjwLau0q2YnKNemLyue89oq6GdXZiutLGMmp6aoZ6owW7DwK2aoaWRo3qnu9Fmqq2qn6CycK%2FOpqSepqSo